European registry for people with amyloidosis
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study collects health information from people who may have amyloidosis or who already have a confirmed diagnosis. It aims to better understand amyloidosis in real-world care across European centers, which can help future patients and treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult patient under legal protection (guardianship/curatorship) or meet the study’s required patient status
- Be seen at a participating hospital for suspected amyloidosis, and sign the “Prospective Cohort” consent
- OR already be followed at the center with a confirmed amyloidosis diagnosis, and sign the “Retro-prospective Cohort” consent
- OR be a deceased patient who was followed at the center with a confirmed amyloidosis diagnosis
- You must not have refused participation
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information from people with a specific type of heart disease called cardiac amyloidosis (AL or ATTR type). By joining a registry, you help doctors learn more about these conditions and how to better treat them.
This study is a registry that collects information from people with cardiac amyloidosis. It helps doctors learn more about the condition and how to better treat it.
This study measures how well the heart’s tiny blood vessels work in people with cardiac amyloidosis, using special heart testing. It may help doctors understand the disease better and improve how patients are evaluated over time.
This study looks at how cardiac amyloidosis shows up on heart imaging, especially ultrasound (echocardiography). It may help doctors better describe and track the condition using your exam and test results.
This study tests whether a 12-week supervised exercise program is safe and helpful for people with cardiac amyloidosis and heart failure. It aims to see if regular exercise can improve how you feel and function.
This study looks at how often blood clots form in the hearts of people with cardiac amyloidosis (a disease where abnormal proteins build up in heart tissue). Understanding clot risk may help doctors better protect patients from stroke and other complications.
Hear when a new Cardiac Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.